论文部分内容阅读
近年来对何杰金氏病治疗的成功,导致了尝试给非何杰金氏淋巴瘤规定定义和给予更精确的治疗.这些肿瘤是一组参差不齐的新生物,自然病史不同,治疗反应也不同.关于这些新生物的数目和定义,从医学文献上所见的多种分类可见有很多争论.在这些淋巴瘤中可以认为消化道弥漫性组织细胞性淋巴瘤(DHL)是一种独特而有些独立的疾病实体.必须说明,在开始时这种实体并不是组织细胞的恶性肿瘤,肿瘤中找到的大细胞几乎都是从淋巴细胞衍化而来,而真正的组织细胞的淋巴瘤极为罕见.这些肿瘤称之为弥漫性大细胞性淋巴瘤可能更好.这样就能把其他分类法所称的肿瘤,如大而分裂的和大而未分裂的滤泡细胞
The success of the treatment of Hodgkin’s disease in recent years has led to attempts to define non-Hodgkin’s lymphomas and to provide more precise treatments. These tumors are a heterogeneous set of new organisms with different natural history and treatment responses. Also different. With regard to the number and definition of these new organisms, there are many controversies from the various classifications seen in the medical literature. In these lymphomas, it can be considered that DHL is a unique type of digestive tract. Some independent disease entities must state that at the beginning this entity was not a malignant tumor of histiocytic cells. The large cells found in the tumor were almost exclusively derived from lymphocytes, whereas the lymphomas of true histiocytic cells were extremely rare. These tumors may be better called diffuse large cell lymphomas. This can be called tumors in other classifications, such as large, dividing and large, undivided follicular cells.